Specialty Overview

Best Hospitals for Multiple Myeloma Treatment in Delhi NCR, India

35 hematology hospitals in our India network are listed in Delhi NCR, accredited by JCI, NABH, NABL, ISO, with 17,362 beds combined.

35
Hospitals Listed
1
City
4.5
Avg. Rating
4
Accreditation Types
The Short Answer

This page lists the hematology hospitals in our directory offering Multiple Myeloma Treatment in Delhi NCR, India, including Apollo Hospitals, Medanta - The Medicity, Artemis Hospital, Fortis Memorial Research Institute and others. Each listing links through to the hospital's full profile page.

Ask us about multiple myeloma treatment in Delhi NCR, India

Share a few details and our care coordination team will get back to you with next steps.

Top Hospitals for Multiple Myeloma Treatment in Delhi NCR, India

🇮🇳 Apollo Hospitals

New Delhi, India 4.9 (1240 reviews) 1,000 beds
Why consider this hospital?
4.9/5 rating from 1240 reviews1,000 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
JCIJoint Commission International accreditationNABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering multiple myeloma treatment can be cared for by Apollo Hospitals's care team in New Delhi, India, from initial consultation through recovery. Apollo Hospitals, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing multiple myeloma treatment.

4.9/5
Rating
1983
Established
1,000
Beds
New Delhi, India
Location
Medanta - The Medicity

🇮🇳 Medanta - The Medicity

Gurgaon, India 4.9 (2150 reviews) 1,600 beds
Why consider this hospital?
4.9/5 rating from 2150 reviews1,600 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
JCIJoint Commission International accreditationNABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering multiple myeloma treatment can be cared for by Medanta - The Medicity's care team in Gurgaon, India, from initial consultation through recovery. Medanta - The Medicity, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing multiple myeloma treatment.

4.9/5
Rating
2009
Established
1,600
Beds
Gurgaon, India
Location
Artemis Hospital

🇮🇳 Artemis Hospital

Gurgaon, India 4.9 (64 reviews) 750 beds
Why consider this hospital?
4.9/5 rating from 64 reviews750 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
JCIJoint Commission International accreditationNABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering multiple myeloma treatment can be cared for by Artemis Hospital's care team in Gurgaon, India, from initial consultation through recovery. Artemis Hospital, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing multiple myeloma treatment.

4.9/5
Rating
2007
Established
750
Beds
Gurgaon, India
Location
Fortis Memorial Research Institute

🇮🇳 Fortis Memorial Research Institute

Gurgaon, India 4.8 (1100 reviews) 1,000 beds
Why consider this hospital?
4.8/5 rating from 1100 reviews1,000 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgeryBariatric SurgeryVascular Surgery
JCIJoint Commission International accreditationNABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering multiple myeloma treatment can be cared for by Fortis Memorial Research Institute's care team in Gurgaon, India, from initial consultation through recovery. Fortis Memorial Research Institute, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing multiple myeloma treatment.

4.8/5
Rating
1996
Established
1,000
Beds
Gurgaon, India
Location
Max Super Specialty Hospital

🇮🇳 Max Super Specialty Hospital

New Delhi, India 4.8 (1300 reviews) 500 beds
Why consider this hospital?
4.8/5 rating from 1300 reviews500 beds
Specialties & Accreditation
CardiacLiver Transplant
JCIJoint Commission International accreditationNABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering multiple myeloma treatment can be cared for by Max Super Specialty Hospital's care team in New Delhi, India, from initial consultation through recovery. Max Super Specialty Hospital, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing multiple myeloma treatment.

4.8/5
Rating
2000
Established
500
Beds
New Delhi, India
Location
All India Institute of Medical Sciences (AIIMS)

🇮🇳 All India Institute of Medical Sciences (AIIMS)

New Delhi, India 4.7 (3500 reviews) 2,400 beds
Why consider this hospital?
4.7/5 rating from 3500 reviews2,400 beds
Specialties & Accreditation
Multi-specialtyResearch
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering multiple myeloma treatment can be cared for by All India Institute of Medical Sciences (AIIMS)'s care team in New Delhi, India, from initial consultation through recovery. All India Institute of Medical Sciences (AIIMS), accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing multiple myeloma treatment.

4.7/5
Rating
1956
Established
2,400
Beds
New Delhi, India
Location
CK Birla Hospital

🇮🇳 CK Birla Hospital

Gurugram, Haryana, India 4.7 (162 reviews) 90 beds
Why consider this hospital?
4.7/5 rating from 162 reviews90 beds
Specialties & Accreditation
Obstetrics & GynecologyOrthopedicsCardiac SciencesOncologyPediatrics
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering multiple myeloma treatment can be cared for by CK Birla Hospital's care team in Gurugram, Haryana, India, from initial consultation through recovery. CK Birla Hospital, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing multiple myeloma treatment.

4.7/5
Rating
2017
Established
90
Beds
Gurugram, Haryana, India
Location
Centre for Sight

🇮🇳 Centre for Sight

Safdarjung Enclave, New Delhi, India 4.7 (181 reviews) 30 beds
Why consider this hospital?
4.7/5 rating from 181 reviews30 beds
Specialties & Accreditation
LASIK SurgeryRetina SurgeryCataract SurgeryGlaucomaCornea Transplant
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering multiple myeloma treatment can be cared for by Centre for Sight's care team in Safdarjung Enclave, New Delhi, India, from initial consultation through recovery. Centre for Sight, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing multiple myeloma treatment.

4.7/5
Rating
1996
Established
30
Beds
Safdarjung Enclave, New Delhi, India
Location
Max Super Specialty Hospital, Gurgaon

🇮🇳 Max Super Specialty Hospital, Gurgaon

Gurgaon, India 4.6 (95 reviews) 104 beds
Why consider this hospital?
4.6/5 rating from 95 reviews104 beds
Specialties & Accreditation
Cardiac SciencesOncologyOrthopedicsNeurosciencesTransplant
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditationJCIJoint Commission International accreditation

Patients considering multiple myeloma treatment can be cared for by Max Super Specialty Hospital, Gurgaon's care team in Gurgaon, India, from initial consultation through recovery. Max Super Specialty Hospital, Gurgaon, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing multiple myeloma treatment.

4.6/5
Rating
2007
Established
104
Beds
Gurgaon, India
Location
Max Super Speciality Hospital, Patparganj

🇮🇳 Max Super Speciality Hospital, Patparganj

Patparganj, New Delhi, India 4.6 (97 reviews) 400 beds
Why consider this hospital?
4.6/5 rating from 97 reviews400 beds
Specialties & Accreditation
Cardiac SciencesOncologyOrthopedicsNeurosciencesTransplant
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditationJCIJoint Commission International accreditation

Patients considering multiple myeloma treatment can be cared for by Max Super Speciality Hospital, Patparganj's care team in Patparganj, New Delhi, India, from initial consultation through recovery. Max Super Speciality Hospital, Patparganj, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing multiple myeloma treatment.

4.6/5
Rating
2005
Established
400
Beds
Patparganj, New Delhi, India
Location

Top Hematology Doctors in Delhi NCR, India

Dr. Rahul Bhargava Featured

Dr. Rahul Bhargava

MBBS, MD (General Medicine), DM (Clinical Hematology), Advanced Fellowship in Unrelated and Haploidentical Transplant
Principal Director & Chief – Hematology · Specialty: Hematologist & BMT Specialist
Fortis Memorial Research Institute Gurgaon, India20+ Years experience
Why consider this doctor?
  • 20+ years of experience in Hematologist & BMT Specialist
  • Principal Director – Hemato-Oncology, Fortis Memorial Research Institute, Gurugram
  • Head of Hematology and BMT, Artemis Hospital, Gurugram
Expertise & Procedures
  • Autologous Bone Marrow Transplant
  • Allogeneic Bone Marrow Transplant
  • Haploidentical BMT
  • Unrelated Donor BMT
  • Peripheral Blood Stem Cell Transplantation
View all procedures →
Hematologist & BMT Specialist Experience: 20+ YearsHospital Affiliation: Fortis Memorial Research InstituteHospital accreditation: JCI, NABH
Image not available

Dr. Arun Singh Danewa

MBBS, MD (Pediatrics), Pediatric Oncology Training, Fellowship in Bone Marrow Transplantation
Sr. Consultant — Pediatric Hematology, Oncology & BMT · Specialty: Pediatric Hematologist & BMT Specialist
Artemis Hospital Gurgaon, India10+ Years experience
Why consider this doctor?
  • 10+ years of experience in Pediatric Hematologist & BMT Specialist
  • Senior Consultant — Pediatric Hematology, Oncology, Bone Marrow Transplant, Artemis Hospital, Gurugram
  • Pediatric Oncology Fellowship, Sir Ganga Ram Hospital, New Delhi
Expertise & Procedures
  • Allogeneic Bone Marrow Transplant
  • Autologous Bone Marrow Transplant
  • Haploidentical Stem Cell Transplant
  • Matched Sibling Donor Transplant for Thalassemia
  • Bone Marrow Aspiration & Biopsy
View all procedures →
Pediatric Hematologist & BMT Specialist Experience: 10+ YearsHospital Affiliation: Artemis HospitalHospital accreditation: JCI, NABH
Image not available

Dr. Gaurav Dixit

MBBS, MD (General Medicine), DM (Clinical Haematology), Professional Certificate in Multiple Myeloma
Head — Haematology Oncology & Bone Marrow Transplant (Unit II) · Specialty: Hematologist & BMT Specialist
Artemis Hospital Gurgaon, India17+ Years experience
Why consider this doctor?
  • 17+ years of experience in Hematologist & BMT Specialist
  • Head — Haematology Oncology & Bone Marrow Transplant (Unit II), Artemis Hospital, Gurugram
  • Senior Consultant — Haematology & BMT, Action Cancer Hospital, Delhi
Expertise & Procedures
  • Autologous Stem Cell Transplant
  • Matched Sibling Allogeneic Stem Cell Transplant
  • Haploidentical Stem Cell Transplant
  • Matched Unrelated Donor Transplant
  • Bone Marrow Aspiration & Biopsy
View all procedures →
Hematologist & BMT Specialist Experience: 17+ YearsHospital Affiliation: Artemis HospitalHospital accreditation: JCI, NABH
Image not available

Dr. Vikas Dua

MBBS, MD (Paediatrics), FNB (Paediatric Hematology Oncology), Fellowship in Paediatric Bone Marrow Transplant, Outreach Programme in Paediatric BMT
Principal Director & Head — Paediatric Haematology, Haemato-Oncology & BMT · Specialty: Pediatric Hematologist & BMT Specialist
Fortis Memorial Research Institute Gurgaon, India20+ Years experience
Why consider this doctor?
  • 20+ years of experience in Pediatric Hematologist & BMT Specialist
  • Principal Director & Head — Paediatric Haematology, Haemato-Oncology and BMT, Fortis Memorial Research Institute, Gurgaon
  • Senior Consultant — Paediatric Hemato-Oncology and BMT, Artemis Hospital, Gurgaon
Expertise & Procedures
  • Allogeneic Bone Marrow Transplant
  • Matched Sibling Donor Transplant
  • Matched Unrelated Donor Transplant
  • Haploidentical Paediatric Stem Cell Transplant
  • Autologous Stem Cell Transplant
View all procedures →
Pediatric Hematologist & BMT Specialist Experience: 20+ YearsHospital Affiliation: Fortis Memorial Research InstituteHospital accreditation: JCI, NABH
Dr. Rayaz Ahmed

Dr. Rayaz Ahmed

MBBS, MD (Pathology), DM (Clinical Hematology)
Director — Hematology & Bone Marrow Transplantation · Specialty: Hematologist & BMT Specialist
Max Super Speciality Hospital, Saket New Delhi, India20+ Years experience
Why consider this doctor?
  • 20+ years of experience in Hematologist & BMT Specialist
  • Director — Hematology & Bone Marrow Transplantation, Max Super Speciality Hospital, Saket, New Delhi
  • Senior Consultant — Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi
Expertise & Procedures
  • Autologous bone marrow / peripheral blood stem cell transplant
  • Allogeneic matched sibling donor stem cell transplant
  • Haplo-identical stem cell transplant
  • Matched unrelated donor stem cell transplant
  • Bone marrow aspiration and biopsy
View all procedures →
Hematologist & BMT Specialist Experience: 20+ YearsHospital Affiliation: Max Super Speciality Hospital, SaketHospital accreditation: NABH, JCI
Image not available

Dr. Ajay Gupta

MBBS, MD, DM, FRACP, Fellowship in Pediatric Bone Marrow Transplantation, Fellowship in Leukemia and Bone Marrow Transplantation
Senior Consultant — Hematology · Specialty: Hematologist & Bone Marrow Transplant Specialist
Indraprastha Apollo Hospital New Delhi, India17+ Years experience
Why consider this doctor?
  • 17+ years of experience in Hematologist & Bone Marrow Transplant Specialist
  • Senior Consultant — Hematology, Indraprastha Apollo Hospital, New Delhi — Present
  • Specialist in Bone Marrow Transplantation and Leukemia Management — Indraprastha Apollo Hospital, New Delhi
Expertise & Procedures
  • Allogeneic Bone Marrow Transplantation
  • Autologous Stem Cell Transplantation
  • Haploidentical Bone Marrow Transplantation
  • Peripheral Blood Stem Cell Mobilization and Harvesting
  • Pediatric Bone Marrow Transplantation
View all procedures →
Hematologist & Bone Marrow Transplant Specialist Experience: 17+ YearsHospital Affiliation: Indraprastha Apollo HospitalHospital accreditation: JCI, NABH
Our Methodology

How we selected these hospitals

A hospital appears on this page when Hematology is among its listed specialties and it is located in Delhi NCR, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.

What To Look For

How to Select the Best Hospital for Multiple Myeloma Treatment in Delhi NCR, India?

Choosing the right hospital for multiple myeloma treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:

International Accreditation

Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.

Specialization

Check that the hospital's listed specialties actually include hematology rather than only general care.

Capacity and Track Record

Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.

Transparent Costs

Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.

Clinical Overview

Understanding Multiple Myeloma Treatment

Multiple Myeloma is a malignancy of plasma cells in the bone marrow, and modern treatment protocols — including VRd (Bortezomib, Lenalidomide, Dexamethasone) induction, Autologous Stem Cell Transplantation (ASCT), and Daratumumab-based regimens — have transformed it from a rapidly fatal disease into a manageable, often remission-sustaining condition, with 5-year survival rates exceeding 55–60% in transplant-eligible patients at high-volume centers.

21–45 days (ASCT phase requires 3–4 weeks inpatient; induction cycles are outpatient-based but require local stay)
Hospital Stay
8–14 weeks from start of induction to safe air travel post-ASCT engraftment; induction-only patients may fly after 4–6 weeks
Total Stay in Country (Fit-to-Fly)
55–65% 5-year overall survival in transplant-eligible patients; Complete Response (CR) rates of 30–45% with VRd induction; ≥Very Good Partial Response (VGPR) rates of 70–80% with Daratumumab-VRd quadruplet therapy
Success Rate

Clinical Overview

  • Multiple Myeloma (MM) is a clonal plasma cell neoplasm in which malignant plasma cells proliferate within the bone marrow, crowding out normal hematopoietic cells and producing dysfunctional monoclonal immunoglobulins (M-protein or paraprotein).
  • This pathological cascade results in the hallmark CRAB criteria: hyperCalcemia, Renal insufficiency (from cast nephropathy and light-chain deposition), Anemia (normocytic, normochromic due to marrow infiltration), and Bone lesions (osteolytic lesions driven by RANKL-mediated osteoclast activation and suppressed osteoblast activity).
  • Beyond CRAB features, patients frequently present with recurrent infections due to humoral immunosuppression, peripheral neuropathy, and fatigue.
Full details →

Who is a Candidate?

  • ELIGIBILITY FOR TRANSPLANT-ELIGIBLE PATHWAY (VRd → ASCT → Maintenance):
  • Age typically ≤70 years (physiological age assessed over chronological age; fit patients up to 75 may qualify after geriatric oncology evaluation)
  • Confirmed diagnosis of symptomatic Multiple Myeloma per IMWG 2014 criteria (presence of CRAB criteria or SLiM criteria: ≥60% clonal plasma cells, sFLC ratio ≥100, >1 focal lesion on MRI)
  • ECOG Performance Status 0–2
  • +24 more

Treatment Options & Approaches

  • INDUCTION THERAPY — VRd (STANDARD TRIPLET) AND DARA-VRd (QUADRUPLET, PREFERRED FOR HIGH-RISK OR FIT PATIENTS):

Recovery

  • PHASE 1 — PRE-TREATMENT WORKUP AND PLANNING (Weeks 1–2): Upon arrival, GAF Healthcare coordinates same-day or next-day specialist consultation with a dedicated Myeloma Program hematologist/oncologist.
  • All diagnostic tests listed (bone marrow biopsy, FISH cytogenetics, PET-CT/WBCT, ECHO, PFTs, SPEP/IFE, sFLC, full biochemistry) are completed within 5–7 business days at the hospital.
  • R-ISS staging is determined, transplant eligibility is formally assessed by a multidisciplinary tumor board (hematology, transplant physician, cardiology, nephrology), and a personalized treatment plan — including regimen selection (VRd vs.

Risks to be aware of

  • Multiple Myeloma treatment with VRd, ASCT, and Daratumumab carries a spectrum of procedure-specific and drug-specific risks that patients must understand prior to initiating therapy.
  • ASCT-related mortality at experienced high-volume centers is now <1–2% (Treatment-Related Mortality, TRM), but the procedure carries significant morbidity during the aplastic phase.
Full details →

Why GAF Healthcare

  • GAF Healthcare provides comprehensive end-to-end non-medical support designed specifically for the complexities of a prolonged oncology treatment journey involving multiple hospital phases, outpatient cycles, and extended country stays.

Common questions about Multiple Myeloma Treatment

What is the cost of Multiple Myeloma Treatment (VRd, ASCT, and Daratumumab) in India vs. the UAE?
The total cost of a complete Multiple Myeloma treatment episode — including VRd or Dara-VRd induction chemotherapy, peripheral blood stem cell mobilization and apheresis, high-dose Melphalan conditioning, Autologous Stem Cell Transplantation (ASCT), BMT unit hospitalization, supportive medications, and standard post-transplant monitoring — ranges from approximately USD 18,000 to USD 45,000 in India, depending on the specific regimen (VRd vs. quadruplet Dara-VRd), the number of induction cycles, response assessments required, and any complications during the ASCT phase. The same treatment in the UAE (Dubai or Abu Dhabi) costs approximately USD 45,000 to USD 95,000, reflecting premium hospital infrastructure, higher drug acquisition costs for imported branded biologics (Daratumumab branded as Darzalex is significantly more expensive in the UAE than in India, where domestic pricing controls and biosimilar availability reduce costs substantially), and higher facility overheads. India offers 50–65% cost savings while maintaining equivalent clinical outcomes at JCI and NABH-accredited transplant centers performing hundreds of ASCTs annually. The UAE offers premium-tier facilities with DHA and JCI accreditation, particularly advantageous for patients from GCC countries who prefer proximity, Arabic-language services, and luxury clinical environments. GAF Healthcare provides detailed cost projections for each individual patient after reviewing their diagnostic reports and proposed treatment plan, ensuring full cost transparency before any commitment.
How long do I need to stay in the country before I am fit to fly home after Multiple Myeloma treatment?
The required in-country stay depends on which phase of treatment is being undertaken. For patients receiving induction chemotherapy only (VRd or Dara-VRd without ASCT — applicable to transplant-ineligible patients or those deferring transplant), a minimum stay of 4–6 weeks is required to complete the first 2 induction cycles and confirm initial response and tolerability, after which the patient may return home and continue maintenance therapy locally with remote follow-up via GAF Healthcare's telemedicine service. For patients undergoing the full VRd induction + ASCT pathway, the total mandatory in-country stay is significantly longer: approximately 10–14 weeks (approximately 2.5 to 3.5 months). This breaks down as: 6–8 weeks for induction chemotherapy (outpatient, local stay required), 1 week for stem cell mobilization and apheresis, 3–4 weeks of inpatient hospitalization for ASCT conditioning and engraftment, and a further 4–6 weeks of post-ASCT outpatient monitoring before fit-to-fly clearance is granted. Patients are declared fit to fly at approximately Day +60 to Day +90 post-ASCT, provided the following criteria are met: stable neutrophil engraftment (ANC >1.0 × 10⁹/L), platelet count >75 × 10⁹/L without transfusion support, no active infection or fever, resolution of significant mucositis and GI complications, ability to self-administer oral medications, and availability of an equivalent standard of emergency hematological care at the home destination. Long-haul flights with prolonged immobility carry a VTE risk — LMWH prophylaxis for flights exceeding 4 hours is routinely recommended for all myeloma and post-ASCT patients. GAF Healthcare's medical coordinator manages all fit-to-fly certifications, airline communication for medical assistance requirements, and coordination with the home country physician for seamless handover.
What is the success rate of Multiple Myeloma treatment with VRd, ASCT, and Daratumumab?
Multiple Myeloma response rates and long-term outcomes have improved dramatically over the past decade with modern triplet and quadruplet regimens. The key outcome benchmarks at high-volume centers in India and the UAE are as follows: With VRd induction (3–4 cycles), approximately 70–80% of patients achieve at least a Very Good Partial Response (VGPR), and 30–45% achieve a stringent Complete Response (sCR) or Complete Response (CR) before transplant. The addition of Daratumumab (Dara-VRd quadruplet) increases pre-transplant MRD negativity rates to approximately 70–75% (vs. 45–50% with VRd alone), as demonstrated in the PERSEUS trial (2024), representing a landmark improvement in response depth. Following ASCT with high-dose Melphalan conditioning, post-transplant sCR/CR rates reach 60–70% in patients who responded well to induction. With Lenalidomide maintenance post-ASCT, the median Progression-Free Survival (PFS) is approximately 54–66 months (4.5–5.5 years) in standard-risk patients, and 5-year Overall Survival (OS) is 55–65% across all risk groups. For standard-risk patients (no high-risk cytogenetics), 5-year OS exceeds 70–75%. For transplant-ineligible patients on Dara-Rd (MAIA trial), median PFS reached 61.9 months with OS rates of approximately 66.3% at 5 years. It is important to note that Multiple Myeloma remains an incurable disease for the vast majority of patients with current technology, but it is highly treatable and controllable, with many patients living 10+ years with excellent quality of life on sequential therapies. Patients with high-risk cytogenetics — particularly del(17p) or gain(1q21) — have shorter median PFS (typically 24–36 months) and should be counseled about clinical trial options, tandem ASCT, or early consideration of CAR-T cell therapy or bispecific antibodies at relapse. GAF Healthcare only works with centers that report outcomes aligned with or exceeding international EBMT and CIBMTR benchmarks.

How GAF Healthcare Assists in Choosing the Best Hospital for Multiple Myeloma Treatment in Delhi NCR, India

Discover the Top Hospitals for Multiple Myeloma Treatment in Delhi NCR, India

This page lists 35 accredited hematology hospitals in Delhi NCR, India, so you can compare accreditation, specialties and bed capacity in one place.

Support When You Need It Most

Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.

Transparent, All-Inclusive Costs

We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.

Visa, Travel and Stay Coordination

Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.

Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.

Patient Success Story

Iraqi Family's Journey: Baby Ibrahim's Life-Saving Heart Surgery in India
Common Questions

Frequently asked questions about multiple myeloma treatment in Delhi NCR, India

How many hematology hospitals are listed in Delhi NCR, India?
35 hospitals in our Delhi NCR, India directory are currently listed for hematology including Multiple Myeloma Treatment.
How do you choose which hospitals to list?
A hospital appears on this page when Hematology is among its listed specialties and it is located in Delhi NCR, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How much does treatment cost in India?
Cost varies by hospital, city and individual case. Use our cost calculator for a personalized estimate — see the link on this page.
Are there hematology hospitals for this in other India cities?
See the "Hospitals in other cities" links on this page for the full India list.
Are these hospitals internationally accredited?
Hospitals listed on this page carry accreditations including JCI, NABH, NABL, ISO — see the accreditation badge shown for each hospital below.
Can I get a treatment plan and cost estimate before I travel?
Yes. Share your medical reports with the GAF Healthcare team over WhatsApp or email, and our medical team will review them and come back with a recommended hospital, a treatment plan and an itemised cost estimate before you commit to anything.
Do you help with visa, travel and accommodation?
Yes. Once you choose a hospital, our team helps arrange the medical visa invitation letter, book accommodation near the hospital, and organise airport pickup and transport to appointments.
What support do I get during and after treatment?
Our medical team reviews your reports and stays in touch throughout your treatment journey — from the first consultation through recovery, including after you return home.
What does the "Featured" label next to a hospital's name mean?
"Featured" reflects editorial prominence on this listing, not a clinical ranking or a claim that it is the "best" hospital.
How do I get matched with the right hospital for multiple myeloma treatment?
Share your medical reports and requirements with the GAF Healthcare team, and our medical coordinators will recommend a suitable hospital from this list based on your case.
Does the listed cost cover everything?
The figures shown are an indicative planning estimate, not a final quote from a specific hospital. Our team provides a single, itemised, all-inclusive quote before you make any commitment.
🤔

Still have questions?

Our coordinators are here to answer your questions about multiple myeloma treatment in Delhi NCR, India.

Next Step

Share your medical reports with us and our team will recommend a hospital and treatment plan for multiple myeloma treatment in Delhi NCR, India.

Contact us to report an inaccuracy on this page.